These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

321 related articles for article (PubMed ID: 24236158)

  • 1. The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells.
    Chen S; Zhao Y; Gou WF; Zhao S; Takano Y; Zheng HC
    PLoS One; 2013; 8(11):e79781. PubMed ID: 24236158
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ING5-mediated antineuroblastoma effects of suberoylanilide hydroxamic acid.
    Wu JC; Jiang HM; Yang XH; Zheng HC
    Cancer Med; 2018 Sep; 7(9):4554-4569. PubMed ID: 30091530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by targeting homologous recombination DNA repair in ovarian cancer.
    Konstantinopoulos PA; Wilson AJ; Saskowski J; Wass E; Khabele D
    Gynecol Oncol; 2014 Jun; 133(3):599-606. PubMed ID: 24631446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy.
    Chen MY; Liao WS; Lu Z; Bornmann WG; Hennessey V; Washington MN; Rosner GL; Yu Y; Ahmed AA; Bast RC
    Cancer; 2011 Oct; 117(19):4424-38. PubMed ID: 21491416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells.
    Lu H; Yang XF; Tian XQ; Tang SL; Li LQ; Zhao S; Zheng HC
    Oncotarget; 2016 Aug; 7(35):56508-56525. PubMed ID: 27447743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis through both mitochondrial and Fas (Cd95) signaling in head and neck squamous carcinoma cells.
    Gillenwater AM; Zhong M; Lotan R
    Mol Cancer Ther; 2007 Nov; 6(11):2967-75. PubMed ID: 18025281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the histone deacetylase inhibitor (S)-2 against LNCaP and PC3 human prostate cancer cells.
    Laurenzana A; Balliu M; Cellai C; Romanelli MN; Paoletti F
    PLoS One; 2013; 8(3):e58267. PubMed ID: 23469273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAHA and/or MG132 reverse the aggressive phenotypes of glioma cells: An in vitro and vivo study.
    Yang XF; Zhao ZJ; Liu JJ; Yang XH; Gao Y; Zhao S; Shi S; Huang KQ; Zheng HC
    Oncotarget; 2017 Jan; 8(2):3156-3169. PubMed ID: 27911270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suberoylanilide hydroxamic acid increases anti-cancer effect of tumor necrosis factor-α through up-regulation of TNF receptor 1 in lung cancer cells.
    You BR; Han BR; Park WH
    Oncotarget; 2017 Mar; 8(11):17726-17737. PubMed ID: 28099148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo.
    Tzao C; Jin JS; Chen BH; Chung HY; Chang CC; Hsu TY; Sun GH
    Dis Esophagus; 2014; 27(7):693-702. PubMed ID: 24033428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
    Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
    Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation.
    Richon VM; Sandhoff TW; Rifkind RA; Marks PA
    Proc Natl Acad Sci U S A; 2000 Aug; 97(18):10014-9. PubMed ID: 10954755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Suberoylanilide hydroxamic acid-induced specific epigenetic regulation controls Leptin-induced proliferation of breast cancer cell lines.
    Feng X; Han H; Zou D; Zhou J; Zhou W
    Oncotarget; 2017 Jan; 8(2):3364-3379. PubMed ID: 27926517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anticancer effects of the MHY218 novel hydroxamic acid-derived histone deacetylase inhibitor in human ovarian cancer cells.
    Jeon HS; Ahn MY; Park JH; Kim TH; Chun P; Kim WH; Kim J; Moon HR; Jung JH; Kim HS
    Int J Oncol; 2010 Aug; 37(2):419-28. PubMed ID: 20596669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel suberoylanilide hydroxamic acid histone deacetylase inhibitor derivative, N25, exhibiting improved antitumor activity in both human U251 and H460 cells.
    Zhang S; Huang WB; Wu L; Wang LY; Ye LB; Feng BH
    Asian Pac J Cancer Prev; 2014; 15(10):4331-8. PubMed ID: 24935393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells.
    Zhou Q; Dalgard CL; Wynder C; Doughty ML
    BMC Neurosci; 2011 May; 12():50. PubMed ID: 21615950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine.
    Ahrens TD; Timme S; Hoeppner J; Ostendorp J; Hembach S; Follo M; Hopt UT; Werner M; Busch H; Boerries M; Lassmann S
    Epigenetics; 2015; 10(5):431-45. PubMed ID: 25923331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
    Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
    Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (Vorinostat, SAHA) profoundly inhibits the growth of human pancreatic cancer cells.
    Kumagai T; Wakimoto N; Yin D; Gery S; Kawamata N; Takai N; Komatsu N; Chumakov A; Imai Y; Koeffler HP
    Int J Cancer; 2007 Aug; 121(3):656-65. PubMed ID: 17417771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time- and residue-specific differences in histone acetylation induced by VPA and SAHA in AML1/ETO-positive leukemia cells.
    Barbetti V; Gozzini A; Cheloni G; Marzi I; Fabiani E; Santini V; Dello Sbarba P; Rovida E
    Epigenetics; 2013 Feb; 8(2):210-9. PubMed ID: 23321683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.